• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Dyax Corp. (DYAX) - Financial and Strategic SWOT Analysis Review - Product Image

Dyax Corp. (DYAX) - Financial and Strategic SWOT Analysis Review

  • Published: March 2013
  • Region: Global
  • 49 pages
  • GlobalData

FEATURED COMPANIES

  • CSL Behring
  • Genentech, Inc.
  • Novo Nordisk A/S
  • Pharming Group N.V.
  • Shire Plc
  • ViroPharma Incorporated
  • MORE

Summary

Dyax Corp. (Dyax) is a fully integrated biopharmaceutical company. It develops and markets of novel biotherapeutics for unmet medical needs in the fields of inflammation and oncology. The company's lead product ecallantide is approved under the brand name KALBITOR in the US for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older. Dyax commercialize KALBITOR in the US on its own and through collaborators outside the US. The products and pipeline products of the company utilizes its proprietary phage display technology which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets.

Dyax Corp. Key Recent Developments

Mar 08, 2013: Dyax's COO Ivana Magovcevic-Liebisch To Resign
Feb 13, 2013: Dyax Reports Revenue Of $16m In Q4 2012
Oct 24, 2012: Dyax Reports Revenue Of $13.1m In Q3 2012
Aug 20, 2012: Dyax Announces Senior Management Changes
Jul 19, 2012: Dyax Reports Revenue Of 14m For Q2 2012

This comprehensive SWOT profile of Dyax Corp. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
Dyax Corp. - Key Facts
Dyax Corp. - Key Employees
Dyax Corp. - Key Employee Biographies
Dyax Corp. - Major Products and Services
Dyax Corp. - Pharmaceutical Pipeline Products Data
Dyax Corp., Pipeline Products by Therapy Area
Dyax Corp., Pipeline Products by Development Phase
Dyax Corp. - Medical Equipment Pipeline Products Data
Dyax Corp. Pipeline Products by Equipment Type
Dyax Corp. Pipeline Products by Development Stage
Dyax Corp. - History
Dyax Corp. - Company Statement
Dyax Corp. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Dyax Corp. - Business Description
Dyax Corp. - Corporate Strategy
Dyax Corp. - SWOT Analysis
SWOT Analysis - Overview
Dyax Corp. - Strengths
Strength - Licensing and Funded Research Program
Strength - Innovative Product and Technology
Strength - Strategic Agreements
Dyax Corp. - Weaknesses
Weakness - Dependence on Third Party Manufacturers
Weakness - History of Losses
Dyax Corp. - Opportunities
Opportunity - Robust Pipeline of Products
Opportunity - Increasing Healthcare Expenditure in the US
Opportunity - Emerging Markets
Dyax Corp. - Threats
Threat - Competition and Technological Changes
Threat - Uncertainties in R&D
Threat - Stringent Regulations
Dyax Corp. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Dyax Corp., Recent Deals Summary
Section 5 – Company’s Recent Developments
Dyax Corp., Recent Developments
Mar 08, 2013: Dyax's COO Ivana Magovcevic-Liebisch To Resign
Feb 13, 2013: Dyax Reports Revenue Of $16m In Q4 2012
Oct 24, 2012: Dyax Reports Revenue Of $13.1m In Q3 2012
Aug 20, 2012: Dyax Announces Senior Management Changes
Jul 19, 2012: Dyax Reports Revenue Of 14m For Q2 2012
Apr 24, 2012: Dyax Reports Revenue Of $11.5m For Q1 2012
Feb 29, 2012: Dyax Appoints Burt Adelman As Chief Medical Officer
Feb 22, 2012: Dyax Reports Revenue Of $8.5m In Q4 2011
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Dyax Corp., Key Facts
Dyax Corp., Key Employees
Dyax Corp., Key Employee Biographies
Dyax Corp., Major Products and Services
Dyax Corp., Number of Pipeline Products by Therapy Area
Dyax Corp., Number of Pipeline Products by Development Stage
Dyax Corp., Pipeline Products By Therapy Area and Development Phase
Dyax Corp. Number of Pipeline Products by Equipment Type
Dyax Corp. Pipeline Products by Equipment Type
Dyax Corp. Number of Pipeline Products by Development Stage
Dyax Corp. Pipeline Products by Development Stage
Dyax Corp., History
Dyax Corp., Subsidiaries
Dyax Corp., Key Competitors
Dyax Corp., Ratios based on current share price
Dyax Corp., Annual Ratios
Dyax Corp., Interim Ratios
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Dyax Corp., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Dyax Corp., Pipeline Products by Therapy Area
Dyax Corp., Pipeline Products by Development Phase
Dyax Corp. Pipeline Products by Equipment Type
Dyax Corp. Pipeline Products by Development Stage
Dyax Corp., Performance Chart (2008 - 2012)
Dyax Corp., Ratio Charts
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Dyax Corp., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

XOMA Ltd.
BioInvent International AB
Novo Nordisk A/S
Shire Plc
ViroPharma Incorporated
Genentech, Inc.
Pharming Group N.V.
CSL Behring

Note: Product cover images may vary from those shown

RELATED PRODUCTS